Showing 2644 results
- Key Release /Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +9% (cc3, +7% USD) with core operating income growing +17% (cc, +9% USD)Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core…
- Key Release /Annonce événementielle au sens de l’art. 53 LRAu T2, hausse du chiffre d’affaires de +9% (tcc3, +7% USD) et du résultat opérationnel core de +17% (tcc, +9% USD)Innovative Medicines (IM): hausse du…
- Media Release /Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of…
- Media Release /Full data from the pivotal Phase III PARADIGMS study of Gilenya® (fingolimod) in pediatric MS will be presented for the first time With 54 accepted abstracts, Novartis presence spans from…
- Media Release /Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew…
- Media Release /Chiffre d'affaires net en hausse de 2% (tcc[1], +2% USD), avec une croissance dans toutes les divisions: Cosentyx (USD 556 millions, +83% tcc) a affiché une forte hausse dans toutes ses…
- Media Release /Der Nettoumsatz steigt mit einem Wachstum in allen Divisionen um 2% (kWk[1], +2% USD): Cosentyx (USD 556 Millionen, +83% kWk) wächst in allen Indikationen stark Entresto (USD 128 Millionen, +…
- Media Release /Breakthrough Therapy Designation based on Phase III study showing the three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo1…
- Media Release /Nearly 70% of patients maintained platelet counts of >=30×109/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding More than one-third of patients permanently…
- Media Release /AutonoMe(TM) preloaded IOL delivery system provides easy, intuitive control for precise IOL insertion during cataract surgery New Clareon® IOL in vitro data and early clinical experience to…
Pagination
- ‹ Previous page
- 1
- …
- 202
- 203
- 204
- 205
- 206
- 207
- 208
- …
- 265
- › Next page